A novel recombinant human thrombopoietin therapy for the management of immune thrombocytopenia in pregnancy
Zhangyuan Kong(Qilu Hospital of Shandong University), Ping Qin(Qilu Hospital of Shandong University), Shan Xiao(Qilu Hospital of Shandong University), Hai Zhou(Qilu Hospital of Shandong University), Hong Li(People's Hospital of Shiyan), Renchi Yang(Chinese Academy of Medical Sciences & Peking Union Medical College), Xiaofan Liu(Chinese Academy of Medical Sciences & Peking Union Medical College), Jianmin Luo(Hebei Medical University), Zhichun Li, Guochao Ji, Zhongguang Cui(Qingdao University), Yusheng Bai(Xinjiang Uygur Autonomous Region Uygur Medicine Hospital), Yuxia Wu(Xinjiang Uygur Autonomous Region Uygur Medicine Hospital), Linlin Shao(Qilu Hospital of Shandong University), Jun Peng(Shandong University), Jun Ma, Ming Hou(Qilu Hospital of Shandong University)
Cited by 108
Abstract
/L). It appears that rhTPO ameliorated the bleeding symptoms remarkably, even in the nonresponders. rhTPO was well tolerated. Dizziness, fatigue, and pain at an injection site were reported in 1 patient each. No congenital disease or developmental delays were observed in the infants in a median follow-up of 53 (range, 39-68) weeks. In conclusion, rhTPO is a potentially safe and effective treatment choice for patients with ITP during pregnancy. Our work has paved the way for further study on the clinical application of rhTPO and other thrombopoietic agents for the management of ITP during pregnancy. This study is registered at www.clinicaltrials.gov as NCT02391272.
Related Papers
No related papers found
Powered by citation graph analysis